Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04501679 · ClinicalTrials.gov registry record · Phase 3

A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

A Phase 3 study of Prurigo Nodularis, sponsored by Galderma R&D.

Completed
Registry status
Phase 3
Development phase
274
Enrollment target
20
Study locations

NCT04501679 is a Phase 3 study of Prurigo Nodularis that has completed, run by Galderma R&D. The registered enrollment target is 274 participants, above the 210-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (30% higher). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04501679, a Phase 3 study of Prurigo Nodularis, has completed, sponsored by Galderma R&D.

COMPLETED
Registry status
Phase 3
Development phase
274 participants
Enrollment target
20
Study locations

Study Summary

The primary objective was to assess the efficacy of nemolizumab (CD14152) compared to placebo in participants greater than or equal to (\>=) 18 years of age with prurigo nodularis (PN) after a 16-week treatment period.

Conditions Studied

Prurigo Nodularis

Interventions

  • DRUG Placebo
  • DRUG Nemolizumab

Study Locations (20)

Florida

  • Galderma Investigational Site - Aventura
  • Galderma Investigational Site - Miami
  • Galderma Investigational Site - North Miami Beach
  • Galderma Investigational Site - Ormond Beach

Texas

  • Galderma Investigational Site - Dallas
  • Galderma Investigational Site - Dripping Springs
  • Galderma Investigational Site - Pflugerville

California

  • Galderma Investigational Site - Fountain Valley
  • Galderma Investigational Site - San Diego

Ohio

  • Galderma Investigational Site - Cincinnati
  • Galderma Investigational Site - Dublin

District of Columbia

  • Galderma Investigational Site - Washington D.C.

Illinois

  • Galderma Investigational Site - Chicago

Indiana

  • Galderma Investigational Site - Indianapolis

Kentucky

  • Galderma Investigational Site - Louisville

Trial Details

FieldValue
Enrollment Target 274 participants
Start Date 2020-08-11
Est. Completion 2022-03-31
Phase Phase 3

Sponsor

Galderma R&D

158 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04501679

The ClinicalTrials.gov registry entry for NCT04501679 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 274 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 210-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (30% higher). The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prurigo Nodularis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04501679 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Texas, California.

Frequently Asked Questions

What is clinical trial NCT04501679 about?

NCT04501679 is a clinical study titled "A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)". The primary objective was to assess the efficacy of nemolizumab (CD14152) compared to placebo in participants greater than or equal to (\>=) 18 years of age with prurigo nodularis (PN) after a 16-week treatment period.

What is the current status of trial NCT04501679?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 274 participants. The study started on 2020-08-11. Estimated completion is 2022-03-31.

What conditions does trial NCT04501679 study?

This clinical trial studies the following conditions: Prurigo Nodularis.

What interventions are being tested in trial NCT04501679?

The interventions under investigation include: Placebo (DRUG), Nemolizumab (DRUG).

Who is sponsoring clinical trial NCT04501679?

This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04501679 being conducted?

This trial has 20 study locations across California, District of Columbia, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prurigo Nodularis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prurigo Nodularis

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.